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Estrogens, whether natural or synthetic, clearl inluence reproductive development, senescence,
and carcinogenesis. Pyrethroid insecticides are now the most widely used agents for indoor pest
control, providing potential for human exposure. Using the MCF-7 human breast carcinoma cel
line, we stdied theestrogenic potential ofseveral sthetic pyrethroid mpounds in vitrousig
pS2 mRNA levels as theendpoint. We testedsumitin, tfenvalerate transalletbrin, andperme-
thrin. Nanomolar concentrations ofeither sumithin or fenvalerate were sufficient to increase pS2
expression slighdy above basal levels. At micromolar concentmtions, these two pyrethroid com-
pounds inducedpS2 expression tolevelscomparable to thoseelicited by 10 nM 17f.estradiol (five-
fold). The estrogenic activity ofsumithrin was abolished with co-treatment with an antiestrogen
(ICI 164,384), whereas estrogenic activity offenvalerate was not si y diminished with
antiestrogen co-treatment. In addition, both sumithini and fenvalerate were:able to induce ei
proliferation ofMCF-7 cells in a se-response fashion. Neither perm in nor d-trans allethrin
affectedpS2 expression. Perme hadanoticeable effect oncel proliferation at 100pM, where-
as d-trans allethin slightdy induced MCF-7 cell prolieration at 10 pM, but was toxic at higher
concentrtions. Overall, our studies imply that eachpyrethroid compound is unique in its ability
toinfluenceseveralcellularpathways. Thesefinding suggetthatpyrethroids should beconsidered
to be hormio disrunptors, andtherpotentidal to affect edocrine fimction n' human andwidlif
should be inivestigated. Key word 173-estradiol, MCF-7 human breast carcinoma cells, pS2,
pyrethroid, RNA. Environ Health Perspect 107:173-177 (1999). [Online 21 January 1999]
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Reproductive dysfunction involving expo-
sure to hormonally active compounds has
been documented extensively in wildlife (1)
and has been implicated in human breast
cancer (2-4) and decreases in male-to-female
birth ratio (5). As endocrine disruptors,
many kinds ofchemicals have been targeted
forstudy in hormonally responsive bioassays.
Synthetic pyrethroids are analogs of a
natural chemical moiety, pyrethrin, isolated
from the chrysanthemum (6). The natural
pyrethrin structure has been modified to be
highly lipophilic and photostable, creating
an effective pesticide and resulting in an
increased presence in the environment (6).
Human exposure to pyrethroid compounds
is extensive. Worldwide, they are used as
insecticides against ticks (7), mites (8), mos-
quitoes (found in bednetting as a control
against malaria) (9,10), and as treatment for
human head lice (11) and scabies (12).
Several studies on the effects of
pyrethroids on thyroid hormone regulation
and androgen function have been reported.
Using rat models, Kaul et al. (13) showed
fenvalerate to increase triiodothyronine (T3)
and thyroxine (T4) levels in circulation
inducing thyroid dysfunction (13). Aktar et
al. (14) found that X-cyhalothrin and bifen-
thrin reduced serum levels ofT3 and T4 in
the rat, whereas only X-cyhalothrin could
decrease the T4/T3 ratio (14). Among
humans, a pyrethroid compound was
suggested to be the causal agent for gyneco-
mastia in a group of Haitian men (15).
Furthermore, several pyrethroid compounds
appear to competitively inhibit testosterone
binding to the androgen receptor and sex
hormone binding globulin at high concen-
trations (16). Although limited, these reports
suggest that some pyrethroid compounds are
capable ofdisruptingendocrine function.
In a previous study using the Ishikawa
Variant-I human endometrial carcinoma
cell line, Garey and Wolff(17) showed that
certain pyrethroid compounds have estro-
genic potential. Since pyrethroid com-
pounds have been shown to affectendocrine
homeostasis, the purpose of our study was
to confirm and further characterize the
estrogenic potential of four synthetic
pyrethroid compounds. Sumithrin, fen-
valerate, d-trans allethrin, and permethrin,
illustrated in Figure 1, were assayed for their
ability to induce pS2 gene expression in
MCF-7 cells. The MCF-7 human breast
carcinoma cell line is a well-established in
vitro system characterized by its estrogen
responsiveness through expression of the
estrogen receptor (ER) (18). The MCF-7
cells used in our studies express ER as deter-
mined by RNA polymerase chain reaction
(data not shown). In these cells, expression
ofthe pS2 gene product is directly induced
by estrogen at the transcriptional level (19)
and has been used as an end point for
xenoestrogens (20). Furthermore, cell prolif-
eration ofMCF-7 cells was also used to test
the estrogenicityofchemical compounds.
Methods
Cells. MCF-7 cells [American Type Culture
Collection (ATCC); Rockville, MD] were
grown in DMEM (high glucose with L-glu-
tamine) with phenol red, supplemented
with 100 U/ml penicillin, 100 pg/iml strep-
tomycin, 0.1 mM nonessential amino acids,
4 mM L-glutamine, 0.1 mM sodium pyru-
vate, 10 pg/ml insulin, and 10% fetal calf
serum (Gibco BRL, Gaithersburg, MD).
Cells were grown at 370C with 5% CO2 in
a humidified incubator.
pS2 expression assay. MCF7 cells were
plated at 30% confluency, supplemented
with phenol red-free DMEM containing
5% charcoal dextran-stripped calf serum
(CDSCS), and incubated for 3 days. After 3
days, fresh phenol red-free DMEM with
5% CDSCS was added to the cells along
with the compounds to be tested. For con-
trols, we used ethanol, corn oil, Vista LPA
solvent (Candea Vista Co., Houston, TX),
17j-estradiol (E2; Sigma, St. Louis, MO),
and ICI 164,384 (a gift from A. Wakeling,
Imperial Chemical Industries, Macclesfield,
UK). Purity of the pyrethroid compounds
[sumithrin (95.4% pure), fenvalerate (95.9%
pure), d-trans allethrin (96.5% pure), and
permethrin (95.7% pure)], was taken into
account when determining concentrations.
Sumithrin and permethrin were suspended
in LPA solvent, and fenvalerate was solubi-
lized in corn oil. d-transAllethrin was liquid
at room temperature. The pyrethroid com-
pounds were provided by McLaughlin
Gormley King Co., Minneapolis, Minnesota.
Cells were incubated with the various
compounds for 48 hr. Total RNA was
extracted using TRIzol reagent (Gibco BRL)
according to the manufacturer's protocol. Total
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RNA (20 pg) was fractionated on a 1%
agarose gel containing formaldehyde and
transferred to Nytran (Schleicher & Schuell,
Keene, NH) by capillary action. Membranes
were prehybridized with Rapid Hyb buffer
(Amersham, Arlington Heights, IL) at 65°C
for 2 hr. A radiolabeled probe was added to
the buffer (5 x 106 cpm/ml buffer, final con-
centration), and hybridization was performed
overnight at 650C. Membranes were washed
for 20 min with 2 x standard saline citrate
(SSC), 0.1% sodium dodecyl sulfate (SDS), at
room temperature followed by two washes for
15 min with 1 x SSC, 0.1% SDS, at 65°C;
membranes were then autoradiographed. A
cloned pS2fragment (ATCC) andadoned [-
actin fragment were used as hybridization
probes for Northern analysis. Probes were
labeled by random priming following the
manufacturer's protocol (Boehringher
Mannheim, Indianapolis, IN). Densitometric
analysis was performed using a BioRad
Imaging Densitometer (GS-670; Bio-Rad,
Hercules, CA) andMolecularAnalyst software
(Bio-Rad). To account for variations in RNA
loading, pS2 values were normalized to
the respective actin values. Results are
expressed as the ratio ofcompound tested over
the vehide control (onefold) and as the mean
± standard deviation (SD) ofseveral indepen-
dent assays. Comparisons ofpS2 expression
were made using the t-test (two-tailed, equal
variance) with SAS software (SAS Institute,
Cary,NC).
MCF-7cellproliferation assay. MCF-7
cells (20,000/well) were seeded into
24-well plates and were allowed to attach
for 24 hr. The medium was then replaced
with phenol red-free DMEM containing
CDSCS along with six concentrations of
the pyrethroid compounds (0.001-100
FM). Cell proliferation was determined on
day 6 by counting the number of cells
in each well using a Coulter Counter
Apparatus (model Zi; Coulter Electronics,
Hialeah, FL). All assay results are expressed
as the mean ± SD of three independent
assays performed in duplicate. Comparisons
of MCF-7 cell proliferation results as a
function ofconcentration were made using
ANOVA analyses (Bonferroni statistic for
multiple comparisons) with SAS software.
Results
Based on a previous study using similar
compounds on endometrial cells (17), we
tested fourpyrethroidcompounds at a con-
centration of30 pM and the solvents used
in the commercial preparations as vehicles
for each compound. Two compounds,
sumithrin and fenvalerate, induced pS2
expression approximately fourfold as com-
pared to the 10-nM E2-positive control,
which induced pS2 expression approxi-
mately fivefold. d-trans Allethrin and per-
methrin did not significantly induce pS2
expression above the negative control. The
solvents, either a petroleum distillate (LPA
solvent) or corn oil, used as vehides for the
various compounds were also tested and
were found to have neither estrogenic nor
inhibitoryactivity(Fig. 2).
To validate their estrogenic response,
either sumithrin or fenvalerate was combined
with ICI 164,384, a pure antiestrogen. Our
results showthat 1 pM ICI 164,384 was suf-
ficient to inhibit E2 (10 nM)-induced pS2
expression (Fig. 3). Likewise, 1 pM ICI
164,384 also inhibited 30 pM sumithrin
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Figure 1. Chemical structures of sumithrin, fen-
valerate, d-transallethrin, and permethrin.
Figure 2. (A) Northern and (B) densitometric
analyses of pS2 expression levels in MCF-7 cells
treated with pyrethroid compounds. Sumithrin (S),
fenvalerate (F), d-transallethtin (d-tA) and perme-
thrin (P) were tested at30 pM; EtOH, corn oil (oil),
or a petroleum distillate (LPA) were used as nega-
tive controls, and 10 nM 171-estradiol (E2) WaS
used as a positive control. The results are the
mean and standard deviation of five independent
assays.
*Pyrethroid compounds with significantly higher levels of pS2
expression then theirvehicles (S in LPA: t= 3.27, p<0.05; F in oil: t=
2.58,p<O.05).
Figure3.(A) Northern and (B) densitometric analy-
ses of pS2 expression levels in MCF-7 cells treat-
ed with pyrethroid compounds. Sumithrin (S; 30
pM), fenvalerate, (F; 30 pM) 17p-estradiol (E2; 10
nM) or these compounds in combination with 1
pM ICI 164,384 were assayed, and EtOH and 1 pM
ICI 164,384 were used as negative controls. The
results are the mean and standard deviation of
threeindependent assays.
*Pyrethroid compounds + ICI 164,384 and E2 + ICI control with sig-
nificantly lower levels ofpS2expression thanthe compounds alone
ISAICI vs. S: t=9.58,p<0.05;FhCI vs. F: t= 1.23,p>O.10; E2+ICI vs. E2:
t= 5.77,p<0.05).
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the effect offenvalerate on pS2 expression in
MCF-7 cells was notaffected bythe addition
ofICI 164,384.
Dose-response curves were performed
with each compound to determine the
minimum concentration necessary to
induce pS2 expression. As shown in Figure
4, concentrations of sumithrin between 1
and 750 nM were able to increase pS2
expression twofold. At concentrations
between 10 and 50 pM, sumithrin was able
to significantly induce pS2 expression to
the level induced by 10 nM E2 (10-fold).
Above 1 pM, fenvalerate induced pS2
expression to levels equivalent to those
induced byE2 (Fig. 4).
Since our initial studies showed that 30
pM d-trans allethrin did not stimulate pS2
expression, we examined whether this
pyrethroid compound could inhibit pS2
gene expression (Fig. 5). When 5 pM d-
trans allethrin was combined with E2 (0.1
nM), it inhibited E2 induction of pS2 by
50%. In the pS2 assays, 0.1 nM E2 was
sufficient to stimulate pS2 expression to
maximal levels (see Fig. 4). To further
investigate d-transallethrin inhibition ofE2
induction of pS2, we performed a d-trans
allethrin dose curve in the absence or pres-
ence of 0.1 nM E2. At concentrations
between 50 nM and 10 pM, d-trans
allethrin alone induced pS2 expression
above basal levels (Fig. 4C). At concentra-
tions above 50 pM, this compound was
toxic to the MCF-7 cells. Moreover, when
increasing amounts of d-trans allethrin
were combined with 0.1 nM E2, d-trans
allethrin was able to significantly inhibit E2
induction ofpS2 down to basal levels.
Permethrin (5 pM) did not induce pS2
or repress E2 (0.1 nM) induction ofpS2 in
initial experiments (Fig. 5). At higher con-
centrations, permethrin weakly induced
pS2 expression in a pattern similar to d-
transallethrin (Fig. 4). In combination with
0.1 nM E2, permethrin had little effect on
pS2 expression levels stimulated byE2.
Another hallmark of estrogenic activity
is the ability to induce MCF-7 cell prolifer-
ation. MCF-7 cells were treated with the
pyrethroid compounds, and cell prolifera-
tion was determined on day 6 during the
logarithmic growth phase (Fig. 6). The LPA
solvent, corn oil, and ethanol were tested
for their ability to affect MCF-7 cell prolif-
eration. All three solvents were unable to
stimulate cell proliferation (data not shown).
Because ethanol was the primary solvent
used for all the pyrethroid compounds, we
used ethanol as the negative control in our
assays. Both sumithrin and fenvalerate
exhibited a strong dose-response trend
toward inducing significant levels of cell
proliferation with increasing concentra-
tions. At a concentration of 10 pM, sum-
ithrin, fenvalerate, and d-trans allethrin
induced cell proliferation comparable to the
10 pM E2; these increases were statistically
significant for all but sumithrin. At concen-
trations below 10 pM, permethrin was
unable to induce MCF-7 cell growth.
While fenvalerate and permethrin signifi-
cantly induced proliferation at 100 pM,
sumithrin and d-transallethrin were toxic at
this concentration.
Discussion
Our studies suggest that certain compounds
of the pyrethroid family possess estrogenic
properties and may function as xenoestro-
gens. Although estrogen is able to directly
stimulate pS2 gene expression and MCF-7
cell proliferation, Kida et al. (21,22) have
shown that the induction ofpS2 expression
is not necessarily correlated with cell prolif-
eration. Using two different assays to test
the estrogenic potential of each pyrethroid
compound, we found that sumithrin was
able to induce both pS2 gene expression and
MCF-7 cell proliferation at nanomolar con-
centrations, maximally at 10 pM. In con-
trast, 500 nM fenvalerate was sufficient to
stimulate pS2 expression to levels similar to
the 10 nM E2 control, but 10 pM fenvaler-
ate was required to significantly induce cell
proliferation. Furthermore, we found that d-
trans allethrin above 1 pM was a moderate
inhibitor of pS2 expression induced by E2,
but could significantly induce cell prolifera-
tion at 10 pM. Permethrin only slightly
affected either end point byexhibiting mod-
est increases in pS2 expression and cell pro-
liferation at 100 pM. The concentrations we
used are similar to the amounts necessary to
observe the estrogenic properties ofvarious
chemicals including o,p'-DDT, pesticides,
and some polychlorinated biphenyls (PCBs)
in various estrogen responsive bioassays.
Whereas the trends produced by each
pyrethroid compound are constant, a degree
ofvariability exists as a result of the differ-
ences in the MCF-7 cellular response from
one experiment to another. Moreover, at the
higher concentrations used, there was a
degree of toxicity to the cells from the
pyrethroid compounds that affected the out-
come of the assays. This variability can be
seen in both the pS2 expression and cell
proliferation assays. Because ofthisvariabili-
ty, both negative and positive controls were
performed for every independent assay.
Within each assay, the induction of pS2
expression or cell proliferation by each
pyrethroid compound remained consistent.
Our studies also revealed that induction
ofpS2 expression bysumithrin andpossibly
fenvalerate in MCF-7 cells can be blocked
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Figure 4. Dose response of pS2 expression levels
in MCF-7 cells by(A) sumithrin; (B)fenvalerate;(C)
d-trans allethrin alone or d-trans allethrin with
17,-estradiol (E2); and(D) permethrin alone or per-
methrin with E2. Each data point represents the
mean and standard deviation ofthree independent
experiments.
by ICI 164,384. This suggests that these
pyrethroid compounds may act through the
dassical estrogen response pathway via the
estrogen receptor. Moreover, fenvalerate may
affect pS2 expression through an alternative
signaling pathway because ICI 164,384 did
not significantly inhibit fenvalerate-induced
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Figure 5. (A) Northern and (B) densitometric
analyses of pS2 expression levels in MCF-7 cells
treated with pyrethroid compounds. d-trans
Allethrin (d-tA; 5 pM), permethrin (P; 5 pM), or 17)3-
estradiol (E2; 0.1 nM) or in combination (d-tA+IE2,
P+IE2) were tested. EtOH and 0.1 nM E2 were used
as the negative and positive controls, respectively.
The results are the mean and standard deviation
ofthree independent assays.
*A+E2 showed a significantly reduced expression (r 3.47, p<0.05),
but not P+E2 (t=O.40,not significant) compared to Es.
pS2 response. Nunez et al. (23) characterized
the pS2 enhancer region and found that pS2
transcription is responsive to estrogen, epi-
dermal growth factor (EGF), the tumor pro-
moter TPA through protein kinase C (PKC)
activation, the c-Ha-ras oncoprotein, and c-
j.un protein. Moreover, there appear to be at
least two regulatory pathways that influence
MCF-7 cell growth and differentiation: an
estrogen-inducible pathway and an
EGF/PKC pathway (24). It is possible that
fenvalerate may be functioning via PKC to
induce pS2 mRNA expression and cell pro-
liferation. In contrast, d-trans allethrin at
1-10 .pM was able to antagonize estrogen
induction ofpS2 expression in a dose-depen-
dent manner, possibly functioning as a com-
petitive inhibitor ofestrogen or by down reg-
ulating ERactivity (2
Our data suggest that structure-activity
relationships (SARs) of these pyrethroid
compounds with estrogen and estrogen
metabolites may explain their various estro-
genic responses in MCF-7 cells. Both DDT
and pyrethroid compounds function as neu-
rToxines,lsaetema and strutrlcmarison bevitween
the two types of chemical compounds has
shown that some pyrethroids and DDT share
similar structural properties and may act on
similar or the same neuroreceptors (6).
Additionally, a study on SARs of the PCB
family of chemical compounds showed that
the ability ofPCBs to activate PKC is depen-
dent on the spatial orientation of the
biphenyl moieties and on the degree and pat-
tern of chlorination (26). Perez et al. (27)
recently proposed that both the length and
the nature of the substituent groups at the
bridging carbon of bisphenol A-related
diphenylalkanes affected the degree of estro-
genicity of these chemical compounds.
Therefore, we propose that certain pyrethroid
compounds that are partially composed of
biphenyl ether moieties may signal through
PKC to affect pS2 mRNA expression and cell
proliferation. Equally important, some
pyrethroid compounds may possess critical
structural properties similar to estrogen
metabolites. Estrogen and its metabolites are
thought to affect DNA binding, induce
DNA damage and DNA repair, and alter the
amounts of enzymes necessary to clear the
metabolites (28). Pyrethroids have structural
components similar to estrogen metabolites
and polyphenols that may explain their estro-
genic response. Whether this is the case
remains to be determined.
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Figure 6. Dose response of MCF-7 cell proliferation by (A) sumithrin; (B) fenvalerate; (C) d-trans allethrin,
or (D) permethrin. 17f(-Estradiol (E2; 10 nM) was used as the positive control. Values shown are means + standard deviations.
*Significant increase in cell proliferation compared with other concentrations (Bonferroni statistic, pct.t5).
Consistent with previous reports show-
ing that certain pyrethroid compounds are
able to affect the endocrine system, we con-
firmed that some pyrethroids (sumithrin,
fenvalerate, and d-trans allethrin) are able
to disrupt estrogen function, whereas
another pyrethroid, permethrin, does not
effect estrogen regulation. Further in vitro
and in vivo research is required to elucidate
the mechanisms by which these novel
xenoestrogens function. Nevertheless,
pyrethroids are widely used, are prevalent
in the environment, and can alter estrogen
homeostasis. Therefore, their effects on the
endocrine system in both humans and
wildlife is ofconcern.
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